1. Home
  2. MDWD vs BHR Comparison

MDWD vs BHR Comparison

Compare MDWD & BHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDWD
  • BHR
  • Stock Information
  • Founded
  • MDWD 2000
  • BHR 2013
  • Country
  • MDWD Israel
  • BHR United States
  • Employees
  • MDWD N/A
  • BHR N/A
  • Industry
  • MDWD Medicinal Chemicals and Botanical Products
  • BHR Real Estate Investment Trusts
  • Sector
  • MDWD Health Care
  • BHR Real Estate
  • Exchange
  • MDWD Nasdaq
  • BHR Nasdaq
  • Market Cap
  • MDWD 195.2M
  • BHR 194.4M
  • IPO Year
  • MDWD 2014
  • BHR N/A
  • Fundamental
  • Price
  • MDWD $19.47
  • BHR $2.67
  • Analyst Decision
  • MDWD Strong Buy
  • BHR
  • Analyst Count
  • MDWD 2
  • BHR 0
  • Target Price
  • MDWD $35.00
  • BHR N/A
  • AVG Volume (30 Days)
  • MDWD 83.0K
  • BHR 434.4K
  • Earning Date
  • MDWD 11-25-2025
  • BHR 11-04-2025
  • Dividend Yield
  • MDWD N/A
  • BHR 7.49%
  • EPS Growth
  • MDWD N/A
  • BHR N/A
  • EPS
  • MDWD N/A
  • BHR N/A
  • Revenue
  • MDWD $19,858,000.00
  • BHR $715,161,000.00
  • Revenue This Year
  • MDWD $21.39
  • BHR N/A
  • Revenue Next Year
  • MDWD $23.01
  • BHR $0.71
  • P/E Ratio
  • MDWD N/A
  • BHR N/A
  • Revenue Growth
  • MDWD N/A
  • BHR N/A
  • 52 Week Low
  • MDWD $14.14
  • BHR $1.80
  • 52 Week High
  • MDWD $22.51
  • BHR $3.82
  • Technical
  • Relative Strength Index (RSI)
  • MDWD 66.30
  • BHR 48.96
  • Support Level
  • MDWD $17.72
  • BHR $2.48
  • Resistance Level
  • MDWD $18.54
  • BHR $2.75
  • Average True Range (ATR)
  • MDWD 0.62
  • BHR 0.09
  • MACD
  • MDWD 0.22
  • BHR -0.02
  • Stochastic Oscillator
  • MDWD 86.01
  • BHR 56.72

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About BHR Braemar Hotels & Resorts Inc.

Braemar Hotels & Resorts Inc is a real estate investment trust company that invests in high revenue per available room, or RevPAR, luxury, upper-upscale and upscale hotels in gateway and resort locations. The firm operates in various U.S. states such as California, Texas, Washington, Philadelphia, Florida, and Illinois as well as Washington, D.C. and St. Thomas, U.S. Virgin Islands. The company operates through its direct hotel investment segment of the hotel lodging industry. Its revenue streams include rooms, food and beverage, and other. The firm's hotels operate under various brands, such as Marriott, Hilton, Courtyard, and, among others.

Share on Social Networks: